HDAC9 and acute myeloid leukemia: After that, HDAC instead of standard-dose cytarabine multiagent chemotherapy has become a common practice in the treatment of AML, especially in patients younger than 60 years of age, either for remission induction or consolidation, based on the guidelines of the National Comprehensive Cancer Network (VI. 2013).